What anxiety disorders are
Anxiety disorders are a group of mental health conditions characterised by excessive and persistent fear, worry, or apprehension that interferes with daily functioning. The main diagnostic categories include generalised anxiety disorder (GAD), social anxiety disorder, panic disorder, agoraphobia, and specific phobias. In the UK, an estimated 5 to 6 per cent of the population meets the criteria for generalised anxiety disorder in any given week, and lifetime prevalence is higher.
Anxiety involves activity across multiple brain regions, including the amygdala, prefrontal cortex, and hippocampus. Neurochemical systems implicated include serotonin, noradrenaline, gamma-aminobutyric acid (GABA), and the endocannabinoid system. Standard evidence-based treatments in the UK, as recommended by NICE, include cognitive behavioural therapy, selective serotonin reuptake inhibitors (SSRIs), and for some presentations, pregabalin or short-term benzodiazepines.
Cannabis research on Anxiety disorders
It provides no cannabis-related evidence.
The published literature contains human experimental laboratory studies, a small number of clinical studies of CBD, and epidemiological data on cannabis and anxiety. No large randomised controlled trial of whole-plant cannabis as a treatment for any anxiety disorder has been published.
CBD and social anxiety: human experimental laboratory studies
A 2011 human experimental study from Brazil tested a single dose of CBD (600 mg oral) against placebo in 24 people with social anxiety disorder who had never received treatment. Participants underwent a simulated public speaking test, a validated experimental model of anxiety. The CBD group showed significantly reduced anxiety, cognitive impairment, and discomfort during the speech, compared with placebo, measured by the Visual Analogue Mood Scale and physiological recordings. This was a human clinical study using an experimental model, not a treatment trial.
A related 2011 human experimental study using SPECT brain imaging found that CBD reduced subjective anxiety and altered cerebral blood flow in limbic and paralimbic regions during a simulated public speaking test in people with social anxiety disorder.
A 2019 review of CBD as a potential treatment for anxiety disorders identified these laboratory findings plus preclinical animal data, but noted that the human evidence was limited to acute single-dose experiments in small groups. No clinical trial of daily CBD dosing for an anxiety disorder had been completed at the time.
THC and anxiety: biphasic effects
Human experimental laboratory studies demonstrate that THC has a biphasic effect on anxiety. At low doses, THC can produce anxiolytic effects in some people under controlled laboratory conditions. At higher doses, THC reliably increases anxiety, fear, and panic-like symptoms in human experimental studies. The dose-response relationship varies between individuals and is influenced by prior cannabis exposure, expectation, and the stressfulness of the testing environment.
Several human laboratory studies have found that CBD can attenuate the anxiogenic effects of THC when the two are co-administered in experimental settings.
Epidemiological and observational evidence
Population-level studies report that people with anxiety disorders are more likely to use cannabis than the general population, and that heavy or frequent cannabis use is associated with an increased risk of developing or worsening anxiety symptoms. These epidemiological associations cannot establish causation: people with anxiety may use cannabis to manage their symptoms, cannabis may contribute to anxiety, or both may share common underlying risk factors.
Human observational reports from people who use cannabis for anxiety describe subjective relief, but these individual accounts do not provide treatment-level evidence.
Animal research
Rodent studies using standard anxiety models (elevated plus maze, conditioned fear, conflict tests) show that CBD produces consistent anxiolytic-like effects across a range of doses. THC in rodents shows the same biphasic pattern seen in humans: low doses reduce anxiety-like behaviour, higher doses increase it. These animal findings help identify mechanisms but do not constitute human treatment evidence.
Compounds studied for Anxiety disorders
CBD is the most studied cannabinoid for anxiety. Human experimental laboratory studies using simulated public speaking have found that a single high dose of CBD (600 mg oral) reduced subjective anxiety in people with social anxiety disorder. CBD’s mechanism in anxiety models is thought to involve serotonin 5-HT1A receptor activation, enhancement of endogenous anandamide signalling, and modulation of limbic and paralimbic brain activity. These are mechanistic hypotheses supported by animal and human imaging data, not a confirmed therapeutic pathway.
THC has been studied in human laboratory research on anxiety and has shown dose-dependent biphasic effects: low doses can reduce anxiety under controlled experimental conditions, while higher doses increase it. THC’s effects on anxiety are mediated through CB1 receptors in the amygdala, prefrontal cortex, and hippocampus.
CBG has not been tested in any human anxiety study. Animal research suggests CBG may have anxiolytic-like effects through alpha-2 adrenoceptor and 5-HT1A receptor activity, but this is preclinical evidence only.
Linalool has been studied in animal models for anxiolytic-like effects, and mouse inhalation studies suggest activity at GABA-A receptors and serotonin pathways. No human anxiety trial of linalool exists.
Limonene has shown anxiolytic-like effects in rodent models, proposed to involve serotonin 5-HT1A receptor activity. Human evidence is absent.
Beta-caryophyllene is a CB2 receptor agonist. Animal research suggests anxiolytic-like and antidepressant-like effects mediated through CB2, but this has not been tested in humans for anxiety disorders.
Limits of the evidence for Anxiety disorders
No randomised controlled trial of cannabis as a treatment for any anxiety disorder has been published. The human evidence for CBD is limited to acute single-dose laboratory experiments using simulated public speaking in people with social anxiety disorder. These experiments demonstrate that CBD can reduce anxiety in a controlled setting for a few hours after a single dose. They do not show that daily CBD use is used for generalised anxiety disorder, panic disorder, agoraphobia, or specific phobias over weeks or months.
The biphasic effect of THC means that dose, setting, and individual factors determine whether THC reduces or increases anxiety. Outside a laboratory, these variables cannot be controlled. The anxiogenic potential of THC at higher doses is a genuine risk for people with anxiety disorders.
The epidemiological literature on chronic cannabis use and anxiety is mixed. Some large studies report a longitudinal association between cannabis use and increased risk of anxiety disorders. Others find no association. None of this evidence establishes whether cannabis or specific cannabinoids can be used safely and effectively as an anxiety treatment.
Sources
1. Bergamaschi MM, Queiroz RHC, Chagas MHN, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-1226. Study record
2. Crippa JAS, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology. 2011;25(1):121-130. Study record
3. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825-836. Study record
4. Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995-1010. Study record
5. Crippa JA, Zuardi AW, Martin-Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Human Psychopharmacology: Clinical and Experimental. 2009;24(7):515-523. Study record
